Search Results - richard+markham

4 Results

Sort By:

A DNA Vaccine for Eliciting T Cell Immunity in the Lung

Unmet NeedRespiratory pathogens are a major contributor to global economic and public health crises. In the wake of the COVID-19 pandemic, new vaccine technologies have been developed to improve the response to emerging pathogens. However, questions remain regarding how to deal with pathogens that have the potential to cause future pandemics. New vaccination...

Published: 3/14/2025 | Inventor(s): Richard Markham, James Gordy, Petros Karakousis

Keywords(s):

Category(s): Clinical and Disease Specializations > Infectious Diseases > Covid-19, Clinical and Disease Specializations > Infectious Diseases > Tuberculosis (TB), Technology Classifications > Therapeutic Modalities > Vaccines

A Vaccine to Reduce Treatment Time for Tuberculosis

Unmet NeedTuberculosis (TB) is one of the leading causes of death globally. A vaccine to prevent TB has not been approved since the development of the BCG vaccine in the early 20th century. New treatment paradigms using small molecule antibiotics have led to cures in a large proportion of individuals with drug-susceptible TB. The course of treatment...

Published: 3/14/2025 | Inventor(s): Richard Markham, Petros Karakousis, Styliani Karanika, James Gordy, Yu-Min Chuang

Keywords(s):

Category(s): Clinical and Disease Specializations > Infectious Diseases > Tuberculosis, Technology Classifications > Therapeutic Modalities > Vaccines, Clinical and Disease Specializations > Infectious Diseases > Tuberculosis (TB)

Compositions and Methods for Treating Melanoma--Further Modifications

Unmet NeedTherapeutic cancer vaccines aim to activate the antitumor T cell response. These vaccines are designed to prime naïve antitumor T cells, by activating antigen presenting cells, particularly dendritic cells (DCs). DNA-based cancer vaccines are a particularly promising approach, partially due to the ease with which they can be manufactured....

Published: 3/14/2025 | Inventor(s): Richard Markham, James Gordy

Keywords(s): Biologics, Cancers, Combination, Disease Indication, Melanoma, Skin Cancer, Therapeutic Matter, Therapeutic Substance, Therapeutics, Therapy Type, Vaccine

Category(s): Clinical and Disease Specializations > Oncology > Melanoma, Clinical and Disease Specializations > Dermatology, Clinical and Disease Specializations > Oncology > Skin Cancer, Technology Classifications > Therapeutic Modalities > Immunotherapies, Technology Classifications > Therapeutic Modalities > Biologics, Technology Classifications > Therapeutic Modalities > Vaccines

Isolation and Application of a Llama-derived Single Domain Antibody Binding to Glycoprotein D of HSV-2

Treatment and Preventative for Herpes Simplex Virus-2JHU REF: 12627Invention Novelty: This technology is an antibody-toxin fusion therapeutic for treatment and prevention of HSV-2.Value Proposition:HSV infects 85% of the global population and 73% of the American population. Currently, there is no cure for HSV infection. This technology is an antibody-based...

Published: 3/13/2025 | Inventor(s): Eileen Geoghegan, Richard Markham

Keywords(s): Antibodies, Biologics, Disease Indication, Herpes Simplex Virus, Herpes Simplex Virus (HSV), Infectious Diseases, Therapeutic Matter, Therapeutic Substance, Therapeutics, Viral Infections

Category(s): Clinical and Disease Specializations, Clinical and Disease Specializations > Infectious Diseases > Herpes Simplex Virus, Clinical and Disease Specializations > Infectious Diseases > Viral Infections, Technology Classifications > Therapeutic Modalities > Antibodies, Technology Classifications > Therapeutic Modalities > Biologics, Clinical and Disease Specializations > Infectious Diseases, Technology Classifications > Therapeutic Modalities